Vnitr Lek 2006, 52(4):313-320

Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy - results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing

J. Krejčí^1,*, L. Groch¹, J. Meluzín¹, T. Vykypěl¹, J. Halámek², J. Vítovec¹

¹ I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta prof. MUDr. J. Vítovec, CSc., FESC

² Ústav přístrojové techniky České akademie věd, Brno, ředitel RNDr. L. Frank, DrSc.

Background:
Percutaneous transluminal septal myocardial ablation (PTSMA) and pacemaker (PM) therapy with apical preexcitation are therapeutic options for hypertrophic obstructive cardiomyopathy (HOCM) patients with symptoms despite pharmacological therapy.

Aim:
Evaluation and comparison of treatment results of PTSMA and PM implantation.


Patients:
22 HOCM patients (NYHA class III and IV) with left ventricle outflow tract gradient (LVOTG) at rest more than 30 mm Hg. In group A were evaluated 11 patients treated by PTSMA. Left ventricle outflow tract gradient (LVOTG) was 90.5 ± 16.0 mm Hg, NYHA class 3.1 ± 0.2. Group B included 11 patients treated by dual chamber PM implantation, LVOTG in this group was 105 ± 48 mm Hg, NYHA class 3.0 ± 0.4.

Results:
NYHA class in the group A decreased after treatment to 1.8 ± 0.6 (p < 0.01), LVOTG to 24 ± 12 mm Hg (p < 0.001). There was observed significant decrease in grade of systolic anterior motion (SAM), interventricular septum (IVS) thickness and left atrium (LA) size. Left ventricle end systolic diameter (LV SD) and left ventricle end diastolic diameter (LV DD) increased during follow-up. Decrease of NYHA class in the group B was to 2.1 ± 0.6 (p < 0.001), LVOTG to 25.5 ± 21.0 mm Hg (p < 0.001). Changes of other parameters in the group B were not significant, except decrease of SAM.


Comparison of both groups:
NYHA class change PTSMA/PM: 1.3 ± 0.6/0.9 ± 0.4 (p < 0.05), LVOTG change PTSMA/PM: -66 ± 20/-79 ± 46 mm Hg (p = n.s.). LV SD assessment - comparison of LV SD change PTSMA/PM: 5 ± 5/1 ± 5 mm (p < 0.05). LA assessment - comparison of LA change PTSMA/PM: -5 ± 5/-1 ± 4 mm (p < 0.05). Other changes were not significant.

Conclusion:
Both therapeutic approaches - PTSMA and PM implantation - resulted in significant improvement of functional capacity assessed by NYHA classification. Decrease of LVOTG was also significant and was similar in both groups, NYHA class improvement as well as LA size decrease and LV DS increase were more expressed in PTSMA group.

Keywords: hypertrophic obstructive cardiomyopathy; percutaneous transluminal septal myocardial ablation; pacemaker therapy

Received: February 10, 2005; Accepted: January 9, 2006; Published: April 1, 2006  Show citation